REaCT
REthinking Clinical Trials

REaCT-TC and TC2

REaCT-TC and TC2

Ciprofloxacin vs G-GCSF during chemotherapy

Principal Investigator(s): Dr. Mark Clemons

ClinicalTrials.gov: NCT02173262
A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.

Sites: Cross Cancer Institute (Edmonton) Northeast Cancer Centre (Sudbury) The Ottawa Hospital Tom Baker Cancer Centre (Calgary)

Tags: Early stage Breast Cancer

Publications:

Systematic Review:

  • Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review. Fernandes et al, 2017. PMID: 27783280

Feasibility results:

  • Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC). Clemons et al, 2018. PMID: 30099602

Clinical Trial results:

  • Manuscript under review